Medicare’s new Bridge program offers GLP-1 weight-loss drugs for $50 a month, but patients with conditions like sleep apnea or Type 2 diabetes are excluded and face much higher costs.
Medicare’s GLP-1 pilot program leaves some patients with serious conditions behind
Medicare’s new Bridge program offers GLP-1 weight-loss drugs for $50 a month, but patients with conditions like sleep apnea or Type 2 diabetes are excluded and face much higher costs.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.